Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2016

Open Access 01-12-2016 | Research

Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer

Authors: Aurélie Pelissier, Aurélie Roulot, Béatrice Guéry, Claire Bonneau, Dominique Bellet, Roman Rouzier

Published in: Journal of Ovarian Research | Issue 1/2016

Login to get access

Abstract

Background

The aim of this study is to evaluate a new tumour marker, HE4, and to compare it with CA125 in predicting optimal cytoreduction and response to chemotherapy. Thirty patients with advanced epithelial ovarian cancer and multiple sera harvested during neoadjuvant chemotherapy (NAC) were included.

Results

Based on ROC curves analysis, CA125 ≤ 75 UI/ml and HE4 ≤ 252 pmol/L after the 3rd cycles of NAC, with a sensitivity of 93.7 % and a specificity of 92.3 % (PPV = 93.7 % and NPV = 92.3 %), offered the best combination for predicting optimal cytoreduction. In addition, the HE4 value of 115 pmol/L is the best cut-off level for identifying platinum-sensitive patients.

Conclusions

The introduction of HE4 as a new tool for predicting platinum-sensitivity and interval optimal cytoreduction is promising.
Literature
1.
Rauh-Hain JA, Krivak TC, del Carmen MG, Olawalye AB. Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol. 2011;4(1):15–21.PubMedPubMedCentral
2.
Lee KR, Tavassoli FA, Prat J, Dietel M, Gersell DJ, Karselatze AI, Hauptmann S, Rutgers J. WHO histological of tumours of the ovary (chapter 2). In: Tassoli FA, Decilee O, editors. In pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003. p. 113–61.
3.
Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RHM, Tholander B, Bast RC, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, Carlo Torre G, Kulpa JK, Tuxen MK, Milona R. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European group on tumor markers. Int J Gynecol Cancer. 2016;26(1):43–51.CrossRefPubMed
4.
Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients. Int J Gynecol Cancer. 2011;21:1040–7.CrossRefPubMed
5.
Milna R, Escudero JM, Augé JM, Filella X, Foj L, Torné A, Lejarcegui J, Pahisa J. HE4 a novel tumour marker for ovarian cancer: comparison with CA125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011;32:1087–95.CrossRef
6.
Zheng H, Gao Y. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease. Int J Gynecol Cancer. 2012;22:1000–5.CrossRefPubMed
7.
Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Milna R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011;57:1534–44.CrossRefPubMed
8.
Chudecka-Glaz A, Rzepka-Gorska I, Wojciechowska O. Human epididymal protein 4 (HE4) is a novel biomarker and a promising prognostic factor in ovarian cancer patients. Eur J Gyneacol Oncol. 2012;33(4):382–90.
9.
Vallius T, Hynninen J, Auranen A, Carpen O, Matomäki J, Oksa S, Virtanen J, Grénman S. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer. Tumor Biol. 2014;35(12):12389–95.CrossRef
10.
Hynninen J, Auranen A, Dean K, Lavonius M, Carpen O, Perheentupa A, Seppänen M, Grénman S. Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21(9):1573–8.CrossRefPubMed
11.
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59.CrossRefPubMed
12.
13.
Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170:974–9.CrossRefPubMed
14.
Vergote I, Tropé C, Amant F, Kristensen G, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS. Neoadjuvant chemotherapy or primary surgery in stage IIIC and IV ovarian cancer. N Engl J Med. 2010;363:943–53.CrossRefPubMed
15.
Tangjitgamol S, Manusirivthaya S, Laopaiboon M, Lumbiganon P, Bryant A. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2016;1, CD006014.PubMed
16.
Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis E, Ioannidis JP. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst. 2006;98:1655–63.CrossRefPubMed
17.
Chi D, Venkatraman E, Masson V, Hoskins W. The ability of preoperativeserum Ca-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol. 2000;77(2):227–31.CrossRefPubMed
18.
Saygili U, Guclu S, Uslu T, Erten O, Demir N, Onvural A. Can serumCa-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol. 2002;86(1):57–61.CrossRefPubMed
19.
Memarzadeh S, Lee SB, Berek JS, Farias-Eisner R. Ca-125 levels are aweak predictor ofoptimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2003;13(2):120–4.CrossRefPubMed
20.
Obeidat B, Latimer J, Crawford R. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum Ca-125 level. Gynecol Obstet Invest. 2004;57(3):153–6.CrossRefPubMed
21.
Gemer O, Segal S, Kopmar A. Preoperative Ca-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2001;80(6):583–5.CrossRefPubMed
22.
Kang S, Kim TJ, Nam BH, Seo SS, Kim BG, Bae DS, Park SY. Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. J Surg Oncol. 2010;101:13–7.CrossRefPubMed
23.
Rodriguez N, Rauh-Hain JA, Shoni M, Berkowitz RS, Muto MG, Feltmate C, Schorge JO, Del Carmen MG, Matulonis UA, Horowitz NS. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012;125:362–6.CrossRefPubMed
24.
Furukawa N, Sasaki Y, Shigemitsu A, Akasaka J, Kanayama R, Kawagucji R, Kobayashi H. CA-125 cut-off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer. J Gynecol Oncol. 2012;24:141–5.CrossRef
25.
Pelissier A, Bonneau C, Chéreau E, de La Motte RT, Fourchotte V, Daraï E, Rouzier R. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. J Gynecol oncol. 2014;135:542–6.CrossRef
26.
Braicu EI, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, Butz H, Cacsire Castillo-Tong D, Mahner S, Zeillinger R, Concin N, Vergote I, Sehouli J. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: Results from the OVCAD study. J Gynecol oncol. 2013;128(2):245–51.CrossRef
27.
Yang Z, Luo Z, Zhao B, Zhang W, Zhang J, Li Z. Diagnosis and preoperative value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer. Oncol Lett. 2013;6:28–34.PubMedPubMedCentral
28.
Angioli R, Plotti F, Capriglione S, Aloisi A, Montera R, Luvero D, Miranda A, Cafa EV, Damiani P, Benedetti-Panici P. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? J Gynecol oncol. 2013;128:579–83.CrossRef
29.
Chudecka-Glaz AM, Cymbaluk-Ploska AA, Menkiszak JL, Sompolska-Rzechula AM, Totoczko-Grabarek AI, Rzepka-Gorska IA. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res. 2014;7:62.CrossRefPubMedPubMedCentral
30.
Abdel-Azeez Hala A, Labib Hany A, Sharaf Samar M, Refaie AN. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev. 2010;11(1):111–6.PubMed
Metadata
Title
Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer
Authors
Aurélie Pelissier
Aurélie Roulot
Béatrice Guéry
Claire Bonneau
Dominique Bellet
Roman Rouzier
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2016
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-016-0270-7

Other articles of this Issue 1/2016

Journal of Ovarian Research 1/2016 Go to the issue

Research

Long-term treatment with testosterone alters ovary innervation in adult pigs

Research

Hypermethylated APC in serous carcinoma based on a meta-analysis of ovarian cancer

Retraction Note

Retraction note: Uterine mast cell tumor: a clinical and cytohistopathological study

Research

Histological analysis of arteriovenous anastomosis-like vessels established in the corpus luteum of cows during luteolysis

Research

Long-term storage does not impact the quality of cryopreserved human ovarian tissue

Research

Establishment and characterization of a cell line (HCH-1) originating from a human clear cell carcinoma of the ovary